Veno-Venous Extracorporeal Life Support Devices Market Size, Share & Trends Analysis Report By Product Type, By Application, By Region, And Segment Forecasts, 2019 To 2025

The global veno-venous extracorporeal life support devices market is expected to witness significant growth over the forecast period. An extracorporeal life support device is a form of extracorporeal support. Extracorporeal life support devices assist in intensive care management of respiratory failure, especially in adult patients.

The working principle of extracorporeal life support is based on an external pump that drains the venous blood from the patient to a membrane oxygenator that is the artificial lung, where the blood is oxygenated and carbon dioxide is removed. The blood is then reverted to the circulation of the patient.

There are basically two forms of extracorporeal life support namely veno-arterial and the other is veno-venous. The factors that drive the growth of the global Veno-Venous Extracorporeal Life Support (VV ECLS) Devices market include increasing patient pool suffering from cardiovascular and cardiopulmonary diseases. These incidences demand the need for cardiopulmonary monitoring and treatment system such as Veno-venous extracorporeal life support devices.

In addition, factors such as smoking, changing lifestyles, rising geriatric population, and increasing disposable income also attribute to the occurrence of cardiopulmonary diseases. Moreover, symptoms such as hypertension, chest pain, shortness in breath, etc. can cause serious health issues. In such conditions, the VV ECLS Devices can be helpful for the patients in order to sustain the body to a standard level.

On the other hand, there are also factors that may hamper the growth of the market such as lack of awareness about Veno-venous extracorporeal life support devices in some regions and also the cost of these devices may restraint the market. The global veno-venous extracorporeal life support devices market is classified on the basis of the type of product, application, end-user, and geography. On the basis of the type of product, the global VV ECLS Devices market is classified as a single-ventricular device and biventricular device. On the basis of application, the global market is classified as a jugular vein, right atrium, femoral vein, and others. On the basis of end-user, the global market is classified as hospitals, clinics, ambulatory surgical centers, cardiac catheterization laboratories, and others.

On the basis of geography, the global veno-venous extracorporeal life support devices market is classified as North America, Latin America, Western Europe, Eastern Europe, the Asia Pacific Excluding Japan, Japan, and the Middle East and Africa.

The North American region comprises the U.S. and Canada. Latin America region comprises Mexico and Brazil. Western European region comprises Germany, Italy, England, Spain, France, and Nordic countries. The Eastern European region comprises Russia, Poland, and the Rest of Eastern Europe. The Asia Pacific Excluding Japan comprises China, India, ASEAN, Australia & New Zealand. The Middle East and Africa comprise GCC, S. Africa, N. Africa, and the Rest of MEA.

In the case of geographical region, North America dominates a major share of the global VV ECLS Devices market. The factors that attribute to the dominant share of North America are owed to an increase in the geriatric population, rising incidence of cardiopulmonary diseases, high demand for innovative products, and government programs to spread awareness regarding the risk associated with cardiopulmonary diseases.

On the other hand, the Asia Pacific region exhibits significant growth rates for veno-venous extracorporeal life support devices market due to the increasing aging population, rising occurrence of cardiovascular and cardiopulmonary diseases, and also expanding awareness and high demand for these devices. 

Some of the prominent players that fuel the growth of the global market include MAQUET Holding B. V. & Co. KG, MedosMedizintechnik AG, Sorin Group, Microport Scientific Corporation, Medtronic, Plc., Terumo Cardiovascular Systems Corporation, and Nipro Medical Corporation.